Microfluidizer processors enable researchers to accomplish the previously impossible, such
as the development of innovative methods for targeted drug delivery using multi-functional
nanomedicine.
More than 1,100 pharmaceutical companies — including 19 of the top 20 — rely on
Microfluidization technology as the undisputed gold standard for uniform particle size
reduction for nanoemulsions, dispersions, nanoencapsulation and cell disruption. Customers
such as Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck,
Novartis, Pfizer, Schering-Plough and Wyeth have all published the use of our dedicated
pharmaceutical homogenizers/processors to develop and produce well-known drugs and vaccines
on the market today.
From startups to contract manufacturers to global pharma, nearly two-thirds of the more than 3,000 Microfluidizer processors installed worldwide are used for biopharmaceutical applications. By reducing particle size uniformly, we help pharma leaders improve the quality, bioavailability, stability and process efficiency of their drugs.
From startups to contract manufacturers to global pharma, nearly two-thirds of the more than 3,000 Microfluidizer processors installed worldwide are used for biopharmaceutical applications. By reducing particle size uniformly, we help pharma leaders improve the quality, bioavailability, stability and process efficiency of their drugs.
Microfluidizer processors enable researchers to accomplish the previously impossible, such as the development of innovative methods for targeted drug delivery using multi-functional nanomedicine.
Tab three content - Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
